<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00215930</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-13208</org_study_id>
    <nct_id>NCT00215930</nct_id>
  </id_info>
  <brief_title>The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer</brief_title>
  <official_title>Phase II Study on the Use of Molecular Analyses-Based Customized Chemotherapy in Patients With Stage IV/IIIB (Malignant Pleural Effusion) Non-Small-Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aventis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The standard treatment for non-small cell lung cancer, stage IV or IIIB malignant pleural
      effusion is chemotherapy. The decision to use a regimen is currently determined by toxicity
      or by physician's preference. In this protocol, the treatment regimen will be assigned based
      on the patients' tumor molecular profile. A tumor molecular profile analysis will allow the
      physician to define a specific molecular portrait that shows the genetic basis of the tumor.
      This analysis results in a detailed report that will determine which chemotherapy will be
      assigned to the patient.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation at study entry will include blood tests, computerized tomography (CT) scans or
      other types of scans needed to measure other disease sites. A biopsy of one tumor is required
      for tumor analysis. If the patient's cancer has spread to other locations that may be easier
      to obtain tissue from and be less invasive, then the biopsy specimen may be collected from
      one of several possible locations that may exist within the patient's body. These possible
      sites include lung, bone, liver, adrenal glands, lymph nodes, nodules under the skin, or in
      cases of brain involvement requiring surgery, brain tissue. Sometimes fluids build up between
      the lining of the lung and the lung itself. If this happened to the patient and their doctor
      tells them the fluid should be drained, then this fluid may also be a source of cells we can
      use to analyze the patients cancer. In very rare cases, other sites might be identified.

      Chemotherapy will consist of the assigned two drugs. Chemotherapy will be repeated every
      three or four weeks for at least two times. Patients will then have a CT scan to measure
      their tumor's response. Response can be reduction of tumor size, no change of tumor size, or
      increased tumor size. Doing CT Scans or other tests after every two cycles of chemotherapy
      will assess for response. If we see a favorable response we will continue chemotherapy for a
      maximum of two times after the best response we can see in the patient's tumor. If the
      patient's tumor grows larger, then we discontinue the study and the patient will discuss
      other treatment options with their doctor.

      During treatment, a blood specimen will be obtained to check the patient's blood counts at
      the beginning and end of study, and prior to administration of every dose of chemotherapy.
      Approximately 3 teaspoonfuls (15 mls) of blood will be drawn each time.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Disease Response After a Maximum of Six Cycles.</measure>
    <time_frame>24 Months</time_frame>
    <description>Determine the number of participants for each category of response rates (RR) in newly diagnosed patients with advanced non-small cell lung cancer (NSCLC) who are treated with a chemotherapeutic regimen assigned to them on the basis of expression of the genes ribonucleotide reductase subunit 1 (ERCC1) and excision repair cross-complementing group 1 gene (RRM1) expression. Prior to treatment we measured the level of ERCC1 and RRM1 expression in the patients tumor, on the basis of which the patient would be assigned a specific doublet chemotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>24 Months</time_frame>
    <description>Median Overall Survival of Participants. OS and Progression Free Survival (PFS) probabilities were estimated using the Kaplan-Meier method. For statistical purposes, it is important to note that this trial was not designed to compare outcomes among patients assigned to the different chemotherapies, but rather that molecular analysis directed individualized chemotherapy assignment is feasible and yields promising results in outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>24 Months</time_frame>
    <description>PFS was recorded as the time elapsed from the date of first treatment to the date of first evidence for disease progression or death. OS and PFS probabilities were estimated using the Kaplan-Meier method. For statistical purposes, it is important to note that this trial was not designed to compare outcomes among patients assigned to the different chemotherapies, but rather that molecular analysis directed individualized chemotherapy assignment is feasible and yields promising results in outcomes.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Double Agent Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Molecular Analysis-Directed Chemotherapy Assignment based on gene expression of ERCC1 and RRM1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>Ribonucleotide reductase subunit 1(RRM1)above 16.5 and Excision repair cross-complementing group 1 gene(ERCC1)above 8.7: Treat patients with Docetaxel and Vinorelbine (DV). DV group was treated with vinorelbine (45mg/m2ondays 1 and 15) and docetaxel (60mg/m2ondays 1 and 15) every 28 days.</description>
    <arm_group_label>Double Agent Chemotherapy</arm_group_label>
    <other_name>Navelbine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>RRM1 below 16.5 and ERCC1 above 8.7: Treat patients with Gemcitabine and Docetaxel (GD). GD group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and docetaxel (40 mg/m2 on days 1 and 8) every 21 days.
RRM1 above 16.5 and ERCC1 below 8.7: Treat patients with Docetaxel and Carboplatin (DC). DC group was treated with docetaxel (75 mg/m2 on day 1) and carboplatin (AUC 5 on day 1) every 21 days.
RRM1 above 16.5 and ERCC1 above 8.7: Treat patients with Docetaxel and Vinorelbine (DV). DV group was treated with vinorelbine (45mg/m2ondays 1 and 15) and docetaxel (60mg/m2ondays 1 and 15) every 28 days.</description>
    <arm_group_label>Double Agent Chemotherapy</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Ribonucleotide reductase subunit 1(RRM1) below 16.5, and Excision repair cross-complementing group 1 gene(ERCC1) below 8.7: Patients treated with Gemcitabine and Carboplatin (GC). GC group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and carboplatin (area under the concentration-time curve [AUC] of 5 on day 1) every 21 days.
RRM1 below 16.5 and ERCC1 above 8.7: Treat patients with Gemcitabine and Docetaxel (GD). GD group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and docetaxel (40 mg/m2 on days 1 and 8) every 21 days.</description>
    <arm_group_label>Double Agent Chemotherapy</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Ribonucleotide reductase subunit 1(RRM1) below 16.5, and Excision repair cross-complementing group 1 gene(ERCC1) below 8.7: Patients treated with Gemcitabine and Carboplatin (GC). GC group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and carboplatin (area under the concentration-time curve [AUC] of 5 on day 1) every 21 days.
RRM1 above 16.5 and ERCC1 below 8.7: Treat patients with Docetaxel and Carboplatin (DC). DC group was treated with docetaxel (75 mg/m2 on day 1) and carboplatin (AUC 5 on day 1) every 21 days.</description>
    <arm_group_label>Double Agent Chemotherapy</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically confirmed adenocarcinoma, large cell or squamous cell carcinoma NSCLC;
             as well as be willing to undergo a biopsy to enable customization of chemotherapy;
             unresectable/ metastatic (stage IV or IIIB malignant pleural effusion) NSCLC;

          -  male or female, aged &gt; 18 years;

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1;

          -  adequate bone marrow, hepatic and renal function assessed within 14 days as evidenced
             by the following:

               1. absolute neutrophil count &gt; 1,500/mm3

               2. platelet count &gt; 100,000/mm3

               3. Hemoglobin &gt; 8gm/dl

               4. no evidence of myelodysplastic syndrome or abnormal bone marrow reserve;

               5. creatinine &lt; 1.5 x upper normal limit(UNL)

               6. total bilirubin must be within normal limits

               7. aspartate aminotransferase(AST)Serum glutamic oxaloacetic transaminase(SGOT)
                  and/or alanine aminotranserase (ALT) serum glutamic pyruvic transaminase(SGPT) &lt;
                  2Ã—5 x UNL in the presence of a normal alkaline phosphatase;

               8. alkaline phosphatases &lt; 4 x UNL in the presence of normal AST and ALT; patients
                  with elevations of both alkaline phosphatase and liver enzymes (AST &amp; ALT) will
                  be excluded.

               9. serum calcium &lt; 1.1 x UNL;

          -  at least one unidimensionally measurable lesion;

          -  signed informed consent;

          -  Women of childbearing potential should have negative pregnancy test prior to
             enrollment to study.

          -  Men with partners in the childbearing age group and women of childbearing potential
             must use effective contraception while on treatment and for 6 months thereafter.

          -  previous surgery (more that 30 days before study entry) is allowed but metastatic
             disease must be demonstrated;

          -  previous radiotherapy is allowed if:

               1. end of radiotherapy 21 days or more prior to study entry;

               2. patient has fully recovered from all toxic effects;

               3. at least one of the measurable target lesions is outside the radiation field.

          -  The patient will be enrolled and re-biopsied at the H Lee Moffitt Cancer Center.
             However since the patients are being treated by FDA approved drugs and with regimens
             for which phase I, phase II or phase III data are available the patients may have
             their chemotherapy administered at the their primary (referring) oncologists office.

          -  Complete initial staging work-up within 4 weeks prior to first infusion of
             chemotherapy.

          -  Patient should have a normal Prothrombin Time (PT) and Activated Prothrombin Time with
             Thromboplastin and kaolin (APTT), to enable him to undergo a biopsy.

          -  Peripheral neuropathy &lt; grade I (according to the NCI-Common Terminology Criteria for
             Adverse Events (CTCAE Version 3.0)

          -  Patients with stable brain metastases will be allowed to enroll. Stable brain
             metastases being defined as no progression of brain metastases 28 days after
             conclusion of definitive treatment as documented by a CT Scan or MRI of the Brain

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Prior systemic chemotherapy or immunotherapy for advanced NSCLC, patients may have
             received neoadjuvant or adjuvant therapy but more than 6 months prior to study entry;

          -  Prior malignancies, except cured non-melanoma skin cancer, curatively treated in situ
             carcinoma of the cervix or other cancer curatively treated and with non-evidence of
             disease for at least 3 years;

          -  presence of uncontrolled brain or leptomeningeal metastases;

          -  current peripheral neuropathy and hearing deficit of neural origin, CTCAE v3.0 grade 2
             except if due to trauma;

          -  other serious illness or medical condition, including but not limited to:

               1. congestive heart disease; prior myocardial infarction within 6 months;

               2. history of significant neurologic or psychiatric disorders that would inhibit
                  their understanding and giving of informed consent;

               3. infection requiring I.V. antibiotics and tuberculosis under treatment ongoing at
                  study entry;

               4. untreated superior vena cava syndrome;

               5. active peptic ulcer; unstable diabetes mellitus or other contraindication to high
                  dose corticosteroid therapy such as herpes, herpes zoster, cirrhosis;

               6. hypercalcemia requiring therapy at the time of study entry;

               7. preexisting clinically significant ascites and/or clinical significant
                  pericardial effusion;

          -  patients whose lesion(s) are assessable only by radionuclide scan;

          -  patients with a history of severe hypersensitivity reaction to Taxotere or other drugs
             formulated with polysorbate 80 must be excluded

          -  concurrent treatment with other investigational drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerold Bepler, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center &amp; Research Institute (now at Karmanos Cancer Institute)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org/research--clinical-trials/clinical-trials</url>
    <description>Moffitt Cancer Center Website for Clinical Trials</description>
  </link>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2005</study_first_submitted>
  <study_first_submitted_qc>September 15, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <results_first_submitted>October 8, 2010</results_first_submitted>
  <results_first_submitted_qc>January 27, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 23, 2011</results_first_posted>
  <last_update_submitted>February 20, 2017</last_update_submitted>
  <last_update_submitted_qc>February 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>malignant pleural effusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Pleural Effusion</mesh_term>
    <mesh_term>Pleural Effusion, Malignant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Assignments: High ERCC1 expression and High RRM1 Expression - vinorelbine plus docetaxel (DV); High ERCC1 expression but NOT High RRM1 expression - docetaxel plus gemcitabine (GD); High ERCC1 expression, but HAVE High RRM1 - carboplatin plus docetaxel (DC); High ERCC1 expression and do NOT have High RRM1 - carboplatin plus gemcitabine (GC)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Double Agent Chemotherapy</title>
          <description>Molecular Analysis-Directed Chemotherapy Assignment based on gene expression of Ribonucleotide reductase subunit 1(ERCC1) and Excision repair cross-complementing group 1 gene (RRM1). GD group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and docetaxel (40 mg/m2 on days 1 and 8) every 21 days. DC group was treated with docetaxel (75 mg/m2 on day 1) and carboplatin (AUC 5 on day 1) every 21 days. DV group was treated with vinorelbine (45mg/m2ondays 1 and 15) and docetaxel (60mg/m2ondays 1 and 15) every 28 days. GC group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and carboplatin (area under the concentration-time curve [AUC] of 5 on day 1) every 21 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Double Agent Chemotherapy</title>
          <description>Molecular Analysis-Directed Chemotherapy Assignment based on gene expression.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" lower_limit="38" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Best Disease Response After a Maximum of Six Cycles.</title>
        <description>Determine the number of participants for each category of response rates (RR) in newly diagnosed patients with advanced non-small cell lung cancer (NSCLC) who are treated with a chemotherapeutic regimen assigned to them on the basis of expression of the genes ribonucleotide reductase subunit 1 (ERCC1) and excision repair cross-complementing group 1 gene (RRM1) expression. Prior to treatment we measured the level of ERCC1 and RRM1 expression in the patients tumor, on the basis of which the patient would be assigned a specific doublet chemotherapy.</description>
        <time_frame>24 Months</time_frame>
        <population>All participants were analyzed according to Response Evaluation Criteria in Solid Tumors (RECIST).</population>
        <group_list>
          <group group_id="O1">
            <title>Double Agent Chemotherapy</title>
            <description>Molecular Analysis-Directed Chemotherapy Assignment based on gene expression. Complete Response (CR): disappearance of all target lesions. Partial Response (PR): at least a 30% decrease in the sum of longest diameter (LD) of target lesions taking as reference the baseline sum LD. Progressive Disease (PD): at least a 20% increase in the sum of LD of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Stable Disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as references the smallest sum LD since the treatment started.</description>
          </group>
        </group_list>
        <measure>
          <title>Best Disease Response After a Maximum of Six Cycles.</title>
          <description>Determine the number of participants for each category of response rates (RR) in newly diagnosed patients with advanced non-small cell lung cancer (NSCLC) who are treated with a chemotherapeutic regimen assigned to them on the basis of expression of the genes ribonucleotide reductase subunit 1 (ERCC1) and excision repair cross-complementing group 1 gene (RRM1) expression. Prior to treatment we measured the level of ERCC1 and RRM1 expression in the patients tumor, on the basis of which the patient would be assigned a specific doublet chemotherapy.</description>
          <population>All participants were analyzed according to Response Evaluation Criteria in Solid Tumors (RECIST).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease (SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease (PD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Assessible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Median Overall Survival of Participants. OS and Progression Free Survival (PFS) probabilities were estimated using the Kaplan-Meier method. For statistical purposes, it is important to note that this trial was not designed to compare outcomes among patients assigned to the different chemotherapies, but rather that molecular analysis directed individualized chemotherapy assignment is feasible and yields promising results in outcomes.</description>
        <time_frame>24 Months</time_frame>
        <population>Review of all participants per protocol for Number at risk, Number of events, Number censored.</population>
        <group_list>
          <group group_id="O1">
            <title>Double Agent Chemotherapy</title>
            <description>Molecular Analysis-Directed Chemotherapy Assignment based on gene expression.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Median Overall Survival of Participants. OS and Progression Free Survival (PFS) probabilities were estimated using the Kaplan-Meier method. For statistical purposes, it is important to note that this trial was not designed to compare outcomes among patients assigned to the different chemotherapies, but rather that molecular analysis directed individualized chemotherapy assignment is feasible and yields promising results in outcomes.</description>
          <population>Review of all participants per protocol for Number at risk, Number of events, Number censored.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" lower_limit="6" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS)</title>
        <description>PFS was recorded as the time elapsed from the date of first treatment to the date of first evidence for disease progression or death. OS and PFS probabilities were estimated using the Kaplan-Meier method. For statistical purposes, it is important to note that this trial was not designed to compare outcomes among patients assigned to the different chemotherapies, but rather that molecular analysis directed individualized chemotherapy assignment is feasible and yields promising results in outcomes.</description>
        <time_frame>24 Months</time_frame>
        <population>Review of all participants for Number at risk, Number of events, Number censored.</population>
        <group_list>
          <group group_id="O1">
            <title>Double Agent Chemotherapy</title>
            <description>Molecular Analysis-Directed Chemotherapy Assignment based on gene expression.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS)</title>
          <description>PFS was recorded as the time elapsed from the date of first treatment to the date of first evidence for disease progression or death. OS and PFS probabilities were estimated using the Kaplan-Meier method. For statistical purposes, it is important to note that this trial was not designed to compare outcomes among patients assigned to the different chemotherapies, but rather that molecular analysis directed individualized chemotherapy assignment is feasible and yields promising results in outcomes.</description>
          <population>Review of all participants for Number at risk, Number of events, Number censored.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" lower_limit="6" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 Months</time_frame>
      <desc>Toxicity was recorded according to the Common Terminology Criteria for Adverse Events version 3 (http://ctep.cancer.gov).</desc>
      <group_list>
        <group group_id="E1">
          <title>Double Agent Chemotherapy</title>
          <description>Molecular Analysis-Directed Chemotherapy Assignment based on gene expression.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia - Grade 3</sub_title>
                <description>Causality: Possibly Related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hemoglobin - Grade 3</sub_title>
                <description>Causality: Unknown</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hyperglycemia - Grade 3</sub_title>
                <description>Causality: Unknown</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hypokalemia - Grade 3</sub_title>
                <description>Causality: Unknown</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Leukocytes - Grade 3</sub_title>
                <description>Causality: 1 Probably Related, 4 Unknown</description>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Lymphocytes - Grade 3</sub_title>
                <description>Causality: Unknown</description>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Platelet Count - Grade 3</sub_title>
                <description>Causality: Unknown</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia - Grade 3</sub_title>
                <description>Causality: Probably Related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction - Grade 3</sub_title>
                <description>Causality: Probably Related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Dehydration - Grade 5</sub_title>
                <description>Causality: Possibly Related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>FN-ANC &lt;1.0/Fever &gt;=38.5C - Grade 3</sub_title>
                <description>Causality: 1 Possibly Related, 1 Unknown</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Fatigue - Grade 3</sub_title>
                <description>Causality: 2 Probably Related, 1 Possibly Related, 2 Unknown</description>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hand/Foot Syndrome - Grade 3</sub_title>
                <description>Causality: 1 Probably Related, 1 Definitely Related</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hyponatremia - Grade 3</sub_title>
                <description>Causality: Unknown</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hypoxia - Grade 3</sub_title>
                <description>Causality: Probably Related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>International Normalization Ratio (INR) - Grade 3</sub_title>
                <description>Causality: Unknown</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Lacrimation - Grade 3</sub_title>
                <description>Causality: Probably Related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Nail Changes - Grade 3</sub_title>
                <description>Causality: Definitely Related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Neuropathy-Motor - Grade 3</sub_title>
                <description>Causality: Possibly Related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Neuropathy-Sensory - Grade 3</sub_title>
                <description>Causality: Possibly Related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Neutropenia - Grade 3</sub_title>
                <description>Causality: Probably Related</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Neutropenia - Grade 4</sub_title>
                <description>Causality: Probably Related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Neutrophils - Grade 3</sub_title>
                <description>Causality: Unknown</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pain/Nausea/Vomiting - Grade 3</sub_title>
                <description>Causality: Probably Related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pedal Edema - Grade 3</sub_title>
                <description>Causality: Probably Related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough - Grade 3</sub_title>
                <description>Causality: Probably Related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Death not associated with CTCAE term - Grade 5</sub_title>
                <description>Causality: Probably Related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Dyspnea - Grade 3</sub_title>
                <description>Causality: 1 Probably Related, 1 Unknown</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism - Grade 4</sub_title>
                <description>Causality: Not Related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>RLL DVT - Grade 3</sub_title>
                <description>Causality: Possibly Related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Intracranial Hemorrhage - Grade 5</sub_title>
                <description>Causality: Probably Related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Syncope - Grade 3</sub_title>
                <description>Causality: Possibly Related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>CTCAE (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin - Grade 1</sub_title>
                <description>Causality: Unknown</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hypokalemia - Grade 1</sub_title>
                <description>Causality: Unknown</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Leukocytes - Grade 1</sub_title>
                <description>Causality: Unknown</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Lymphocytes - Grade 1</sub_title>
                <description>Causality: Unknown</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Platelet Count - Grade 1</sub_title>
                <description>Causality: Unknown</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerald Bepler, M.D., via Moffitt Cancer Center</name_or_title>
      <organization>Karmanos Cancer Institute (formerly at Moffitt Cancer Center)</organization>
      <phone>813-745-4398</phone>
      <email>beplerg@karmanos.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

